agrees 25bn guidant deal pharmaceutical giant johnson johnson agreed buy medical technology firm guidant 25 4bn 13bn guidant key producer equipment combat heart problem implant defibrillator pacemaker analyst said deal aimed offsetting johnson johnson's reliance slowing drug business also pointed merger likely drug healthcare industry fragmented pressure cut cost number johnson johnson's product facing patent expiration company also battling fierce competition generic product meanwhile demand defibrillator give heart small electric shock irregular heartbeat rhythm detected expected increase analyst said move johnson johnson widely expected firm pay 76 guidant share wednesday's closing price analyst say u antitrust regulator could force firm shed overlapping stent operation stent tube used keep artery open unblocked